Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB (APOLLO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03469349|
Recruitment Status : Active, not recruiting
First Posted : March 19, 2018
Last Update Posted : March 8, 2019
|Condition or disease||Intervention/treatment||Phase|
|Peripheral Arterial Diseases||Drug: Actovegin Drug: Placebo||Phase 3|
The study will enroll approximately 366 patients. Participants will be randomly assigned to one of the two treatment groups in 1:1 ratio:
- Placebo (dummy inactive substance) - this is a tablet/IV infusion that looks like the study drug but has no active ingredient
All participants will be asked to take IV infusion for 2 weeks followed by oral tablets for 10 weeks.
This multi-center trial will be conducted Russia, Belarussia, Georgia, Ukraine and Kazakhstan. The overall time to participate in this study is 25-26 weeks. Participants will make multiple visits to the clinic, and 12 weeks after last dose of study drug for a follow-up assessment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||366 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Randomized, International, Multicenter, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Subjects With Peripheral Arterial Occlusive Disease Fontaine Stage IIB|
|Actual Study Start Date :||May 1, 2018|
|Estimated Primary Completion Date :||May 31, 2019|
|Estimated Study Completion Date :||September 30, 2019|
Experimental: Actovegin 1200 mg
Actovegin 1200 mg, intravenously (IV), once daily for up to 2 weeks followed by actovegin 200 mg, tablets, orally, thrice daily (TID) (1200 mg/day) for up to 10 weeks.
Actovegin IV infusion and tablets
Placebo Comparator: Placebo
Actovegin placebo-matching, IV, once daily for up to 2 weeks and actovegin placebo-matching tablets, orally, TID for up to 10 weeks.
Actovegin placebo-matching IV infusion and tablets
- Percent Change in Initial Claudication Distance (ICD) from Baseline to Week 12 of Study Treatment [ Time Frame: Baseline, Week 12 ]ICD will be assessed using treadmill testing. ICD is the distance walked at the onset of claudication pain or pain-free walking distance.
- Percent Change in ICD from Baseline to Weeks 2 and 24 After Randomization [ Time Frame: Baseline, Weeks 2 and 24 ]ICD will be assessed using treadmill testing. ICD is the distance walked at the onset of claudication pain or pain-free walking distance.
- Change in Absolute Claudication Distance (ACD) from Baseline to Weeks 2, 12 and 24 [ Time Frame: Baseline, Weeks 2, 12 and 24 ]ACD will be assessed using treadmill testing. ACD is the distance at which claudication pain becomes so severe that the participant is forced to stop, also known as maximal walking distance.
- Proportion of Participants With Rest Pain at Weeks 12 and 24 After Randomization [ Time Frame: Weeks 12 and 24 ]Rest pain is defined as a continuous burning pain, that begins, or is aggravated, after reclining or elevating the limb and is relieved by sitting or standing.
- Proportion of Participants with Revascularization Procedures at Week 24 After Randomization [ Time Frame: Week 24 ]Participants who will undergo revascularization procedures for the treatment of PAD will be reported.
- Change From Baseline in 36-Item Short Form Survey (SF-36) at Weeks 12 and 24 [ Time Frame: Baseline, Weeks 12 and 24 ]SF-36 patient-reported measure of health-related quality of life. It consists of 8 sections: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health, that are the weighted sums of the questions in each health domain. Each scale is directly transformed to a 0 to 100 scale on the assumption that each question carries equal weight. The lower the score, the more disability, and the higher the score, the less disability, ie, a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03469349
|4-th N.E. Savchenko City Clinical Hospital|
|Minsk, Belarus, 220036|
|Minsk, Belarus, 220036|
|Minsk Region Clinical Hospital Department of vascular surgery|
|Minsk, Belarus, 223040|
|High Technology Medical Center; University Clinic|
|Tbilisi, Georgia, 0144|
|Center of Vascular and Heart Disease|
|Tbilisi, Georgia, 0159|
|Tbilisi, Georgia, 0160|
|"National scientific centre of oncology and transplantology"|
|Astana, Kazakhstan, Z05K4F3|
|Regional Clinic Hospital|
|Shymkent, Kazakhstan, X09E1G4|
|NSHI Road clinical hospital at Chelyabinsk station of OAO RZD|
|Chelyabinsk, Russian Federation, 454092|
|BMH Kursk regional clinical hospital of Healthcare department of Kursk region|
|Kursk, Russian Federation, 305007|
|SBHI of Moscow city "City clinical hospital #29 n.a. N.E. Bauman of Moscow Healthcare department|
|Moscow, Russian Federation, 111020|
|SBHI of Moscow healthcare department City clinical hospital #15 n.a. O.M Filatov of Moscow healthcare department|
|Moscow, Russian Federation, 111539|
|A.V. Vishnevsky Institute of Surgery, vessel surgery department|
|Moscow, Russian Federation, 117997|
|SBHI of Moscow Research Institute of Emergency Medicine n.a. N.V. Sklifosofsky of Moscow Healthcare department|
|Moscow, Russian Federation, 129090|
|BHI of Omsk region Regional clinical hospital, vessel surgery department|
|Omsk, Russian Federation, 644111|
|FSBEI HE Rostov State Medical University of MoH of Russia|
|Rostov-on-Don, Russian Federation, 344022|
|SBHI of Ryazan region Regional clinical cardiological dispensary, vessel surgery department/ FSBI of Ryazan Region "Ryazan State Medical Univesity n.a. I.P. Pavlov" of MoH of Russia|
|Ryazan, Russian Federation, 390026|
|Pavlov First Saint Petersburg State Medical University, Faculty surgery chair, cardio-vessel surgery department|
|Saint Petersburg, Russian Federation, 197022|
|SPb SBHI Consulting and diagnostic center #85|
|Saint Petersburg, Russian Federation, 198260|
|North-Western State Medical University named after I.I. Mechnikov|
|Saint-Petersburg, Russian Federation, 191015|
|SPb SBHI City multipurpose hospital #2|
|Saint-Petersburg, Russian Federation, 194354|
|State Healthcare Institution of Saratov region "Region clinical hospitai"|
|Saratov, Russian Federation, 410053|
|Regional Clinical Hospital, Department of Vascular Surgery|
|Dnipro, Ukraine, 49005|
|National Medical University of MoH of Ukraine, Ivano-Frankivsk Regional Clinical Hospital|
|Ivano-Frankivsk, Ukraine, 76008|
|Institute of General and Urgent Surgery of the National Academy of Sciences of Ukraine, department of acute vascular diseases|
|Kharkiv, Ukraine, 61103|
|National Medical University after O.O. Bogomolets, Aleksandrovskaya City Clinical Hospital Dpt of General Surgery|
|Kyiv, Ukraine, 01004|
|National Institute of Surgery &Transplantology, department of surgery of the main vessels|
|Kyiv, Ukraine, 03680|
|Lviv Regional Clinical Hospital, Department of Vascular Surgery|
|Lviv, Ukraine, 79000|
|Zaporizhzhia Regional Clinical Hospital, Regional center of vascular and endovascular surgery|
|Zaporizhzhia, Ukraine, 69050|
|Study Director:||Medical Director Clinical Science||Takeda|